Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #39 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Natco Pharma Limited (this stock) | 14,714 | 16.5 | 15.4% | 0.8% | — | 74 | 81 | 48 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 735 | 186 | 206 | ₹ |
| March 31, 2026 | 739 | 144 | 269 | ₹ |
| Dec. 31, 2025 | 647 | 161 | 151 | ₹ |
| Sept. 30, 2025 | 1,363 | 614 | 518 | ₹ |
| June 30, 2025 | 1,329 | 572 | 480 | ₹ |
| March 31, 2025 | 1,221 | 506 | 406 | ₹ |
| Dec. 31, 2024 | 475 | 164 | 132 | ₹ |
| Sept. 30, 2024 | 1,371 | 818 | 676 | ₹ |
| June 30, 2024 | 1,363 | 804 | 668 | ₹ |
| March 31, 2024 | 1,068 | 478 | 386 | ₹ |
| Dec. 31, 2023 | 759 | 256 | 213 | ₹ |
| Sept. 30, 2023 | 1,031 | 440 | 369 | ₹ |
| June 30, 2023 | 1,140 | 500 | 420 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 4,078 | 1,491 | 1,418 |
| March 31, 2025 | 4,430 | 2,291 | 1,883 |
| March 31, 2024 | 3,999 | 1,674 | 1,388 |
| March 31, 2023 | 2,707 | 862 | 715 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 1,768 | -2,143 | 298 | 388 | 1,380 |
| March 31, 2025 | 1,697 | -1,414 | -211 | 401 | 1,296 |
| March 31, 2024 | 1,212 | -1,033 | -247 | 339 | 872 |
| March 31, 2023 | 849 | -477 | -363 | 146 | 703 |
| March 31, 2022 | 46 | -5 | 35 | 233 | -186 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 11,074 | 9,221 | 9,185 | 606 | 100 | 5,052 | 1,681 | 199 | 2,545 | 908 |
| March 31, 2025 | 8,631 | 7,612 | 7,571 | 273 | 0 | 5,270 | 944 | 120 | 2,432 | 766 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
